Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Dermata Therapeutics, Inc. (DRMA) had Stock-Based Compensation of $0.14M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-1.86M |
|
-- |
|
-- |
|
$1.90M |
|
$-1.90M |
|
$0.04M |
|
$-1.86M |
|
$-1.86M |
|
$-1.86M |
|
$-1.86M |
|
$-1.86M |
|
$-1.86M |
|
$-1.90M |
|
$-1.90M |
|
0.93M |
|
0.93M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$7.86M |
|
-- |
|
-- |
|
$7.86M |
|
$1.64M |
|
-- |
|
-- |
|
$1.64M |
|
$6.22M |
|
$6.22M |
|
$6.22M |
|
2.66M |
|
| Cash Flow Statement Financials | |
$-7.76M |
|
-- |
|
$12.12M |
|
$3.16M |
|
$7.52M |
|
$4.36M |
|
|
Stock-Based Compensation |
$0.14M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.79 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.76M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-29.92% |
|
-29.92% |
|
-23.68% |
|
-29.92% |
|
$2.34 |
|
$-8.38 |
|
$-8.38 |
|